Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains.
The substituted (S)-3-phenylpiperidine (-)-OSU6162 belongs to a novel class of functional modulators of dopaminergic systems. In vivo, (-)-OSU6162 has a unique stabilising profile on dopaminergic functions. In vitro this compound exhibits low affinity for the dopamine D2 receptor, but due to its similarity to neuroleptics on brain dopaminergic neurochemistry and different postsynaptic effects it has been characterised as a preferential dopamine autoreceptor antagonist. To further clarify the effects of (-)-OSU6162 on the postjunctional nigrostriatal dopaminergic system, dopamine receptor binding was measured in rhesus monkeys (Macaca mulatta) by positron emission tomography (PET) using the D1 and D2 dopamine receptor radioligands [11C]SCH23390 and [11C]raclopride respectively, before and during continuous intravenous infusions of(-)-OSU6162. Additionally, the test-retest variability of sequential [11C]SCH23390 scans was estimated. Following the administration of (-)-OSU6162, [11C]raclopride binding in striatum was dose-dependently decreased with a 76% reduction occurring after 3.0 mg/kg per h continuous infusion. Whereas (-)-OSU6162 in the lower doses had no effect on [11C]SCH23390 binding, the highest dose, 3.0 mg/kg per h, increased [11C]SCH23390 binding, which may indicate a potentiating effect on D1 dopamine receptor mediated functions. Thus, in contrast to the conditions in vitro, (-)-OSU6162 produces a high displacement of raclopride from D2 receptors in vivo.
Ekesbo
A
A
Department of Neuroscience, Neurology, University Hospital, Uppsala University, Sweden.
Torstenson
R
R
Hartvig
P
P
Carlsson
A
A
Sonesson
C
C
Waters
N
N
Tedroff
J
J
Långström
B
B
D000818:Animals; D001552:Benzazepines / Q000493:pharmacokinetics*; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D002250:Carbon Radioisotopes; D003342:Corpus Striatum / Q000378:metabolism; D018492:Dopamine Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D007262:Infusions, Intravenous; D008253:Macaca mulatta; D009928:Organ Specificity; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D020891:Raclopride; D011869:Radioligand Assay; D017448:Receptors, Dopamine D2 / Q000032:analysis / Q000378:metabolism*; D015203:Reproducibility of Results; D012457:Salicylamides / Q000493:pharmacokinetics*; D014055:Tomography, Emission-Computed / Q000379:methods
D001552:Benzazepines; D002250:Carbon Radioisotopes; D018492:Dopamine Antagonists; D010880:Piperidines; D017448:Receptors, Dopamine D2; D012457:Salicylamides; C109513:OSU 6162; D020891:Raclopride